Literature DB >> 8408731

Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy.

J G Hardy1, W J Harvey, R A Sparrow, G B Marshall, K P Steed, M Macarios, I R Wilding.   

Abstract

Release of 5-ASA from a sustained release formulation (Pentasa, Ferring A/S, Copenhagen, Denmark) was monitored with plasma sampling for up to 24 hours in nine volunteers under both fasted and fed conditions. Drug absorption was correlated with location of the sustained-release microgranules in the gastrointestinal tract by gamma scintigraphy. Disintegration of the labeled tablet preparation occurred in the stomach within 20 minutes and acetylated 5-ASA was detectable in the plasma less than 60 minutes after ingestion. No significant differences were detected in either transit times through the small intestine, peak plasma acetylated 5-ASA concentration or lag time to absorption between fasted and fed individuals. Peak plasma concentration of acetylated 5-ASA usually occurred when the microgranules were present in the small intestine or ascending colon. The pharmacoscintigraphic study confirmed that 5-ASA release from the formulation occurred throughout the gastrointestinal tract, and that food effects on the in vivo behavior of the preparation were minimal.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408731     DOI: 10.1002/j.1552-4604.1993.tb05612.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  Nuclear medicine techniques in the evaluation of pharmaceutical formulations.

Authors:  A C Perkins; M Frier
Journal:  Pharm World Sci       Date:  1996-06

Review 2.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 4.  Clinical pharmacokinetics of slow release mesalazine.

Authors:  M De Vos
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

5.  Effect of altered gastric emptying and gastrointestinal motility on metformin absorption.

Authors:  P H Marathe; Y Wen; J Norton; D S Greene; R H Barbhaiya; I R Wilding
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 7.  Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.

Authors:  Anitha Sriram; Suma Tangirala; Srividya Atmakuri; Sajid Hoque; Sheela Modani; Saurabh Srivastava; Srushti Mahajan; Indrani Maji; Rahul Kumar; Dharmendra Khatri; Jitender Madan; Pankaj Kumar Singh
Journal:  AAPS PharmSciTech       Date:  2021-11-03       Impact factor: 3.246

8.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

9.  In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy.

Authors:  P H Marathe; E P Sandefer; G E Kollia; D S Greene; R H Barbhaiya; R A Lipper; R C Page; W J Doll; U Y Ryo; G A Digenis
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

10.  [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].

Authors:  J Keller; H Goebell; U Klotz; P Layer
Journal:  Med Klin (Munich)       Date:  1998-05-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.